These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 10893688

  • 21. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 22. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 23. Validity and reliability of the Italian version of the ECOS-16 questionnaire in postmenopausal women with prevalent vertebral fractures due to osteoporosis.
    Salaffi F, Malavolta N, Cimmino MA, Di Matteo L, Scendoni P, Carotti M, Stancati A, Mulé R, Frigato M, Gutierrez M, Grassi W, Italian Multicentre Osteoporotic Fracture (IMOF) Study Group.
    Clin Exp Rheumatol; 2007; 25(3):390-403. PubMed ID: 17631735
    [Abstract] [Full Text] [Related]

  • 24. Validation of the Portuguese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-41) in Brazilian women with postmenopausal osteoporosis with vertebral fracture.
    de Oliveira Ferreira N, Arthuso M, da Silva RB, Pinto-Neto AM, Costa-Paiva L.
    Clin Rheumatol; 2013 Nov; 32(11):1585-92. PubMed ID: 23609409
    [Abstract] [Full Text] [Related]

  • 25. Relationship between quantitative ultrasound parameters at the calcaneus and health-related quality of life in postmenopausal Italian women: the FEDRO study.
    Gonnelli S, Caffarelli C, Tanzilli L, Cadirni A, Guglielmi G, Rossi S, Nuti R.
    Calcif Tissue Int; 2013 Dec; 93(6):487-94. PubMed ID: 23912952
    [Abstract] [Full Text] [Related]

  • 26. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 27. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
    Siris ES, Brenneman SK, Miller PD, Barrett-Connor E, Chen YT, Sherwood LM, Abbott TA.
    J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Association between generic and disease-specific quality of life questionnaires and mobility and balance among women with osteoporosis and vertebral fractures.
    Bergland A, Thorsen H, Kåresen R.
    Aging Clin Exp Res; 2011 Aug; 23(4):296-303. PubMed ID: 22067372
    [Abstract] [Full Text] [Related]

  • 32. Bone structure in patients with low bone mineral density with or without vertebral fractures.
    Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P.
    J Bone Miner Res; 2000 Jul; 15(7):1368-75. PubMed ID: 10893686
    [Abstract] [Full Text] [Related]

  • 33. The relationship between back pain and future vertebral fracture in postmenopausal women.
    Kuroda T, Shiraki M, Tanaka S, Shiraki Y, Narusawa K, Nakamura T.
    Spine (Phila Pa 1976); 2009 Aug 15; 34(18):1984-9. PubMed ID: 19680106
    [Abstract] [Full Text] [Related]

  • 34. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment.
    Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M.
    J Bone Miner Metab; 2005 Aug 15; 23(2):167-73. PubMed ID: 15750696
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 15; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36.
    de Oliveira Ferreira N, Arthuso M, da Silva R, Pedro AO, Pinto Neto AM, Costa-Paiva L.
    Maturitas; 2009 Jan 20; 62(1):85-90. PubMed ID: 19100693
    [Abstract] [Full Text] [Related]

  • 40. Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT.
    Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, Boonen S, Black D, Adachi JD, HORIZON Pivotal Fracture Trial.
    Bone; 2011 Jun 01; 48(6):1298-304. PubMed ID: 21421092
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.